{"id":22987,"date":"2022-01-11T17:00:25","date_gmt":"2022-01-11T14:00:25","guid":{"rendered":"https:\/\/zdmaa.com\/immunotherapy-may-help-elderly-cancer-patients-but\/"},"modified":"2022-01-12T10:45:02","modified_gmt":"2022-01-12T07:45:02","slug":"immunotherapy-may-help-elderly-cancer-patients-but","status":"publish","type":"post","link":"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/","title":{"rendered":"\u0130mm\u00fcnoterapi ya\u015fl\u0131 kanser hastalar\u0131na yard\u0131mc\u0131 olabilir, ancak…"},"content":{"rendered":"

\u0130mm\u00fcnoterapi ya\u015fl\u0131 kanser hastalar\u0131na yard\u0131mc\u0131 olabilir, ancak…<\/span><\/span><\/span><\/span><\/p>\n

\n

c<\/span><\/span><\/span> Ya\u015fland\u0131k\u00e7a kanser riskleri \u00f6nemli \u00f6l\u00e7\u00fcde artar. <\/span>Ulusal Kanser Enstit\u00fcs\u00fcne g\u00f6re, t\u00fcm yeni kanserlerin yar\u0131s\u0131ndan fazlas\u0131 65 ya\u015f ve \u00fcst\u00fc hastalarda te\u015fhis edilir ve yeni vakalar\u0131n y\u00fczde 25’inden fazlas\u0131 75 ya\u015f ve \u00fcst\u00fc hastalardad\u0131r. <\/span>Bu nedenle, her ya\u015ftan hastada \u00e7e\u015fitli kanser t\u00fcrlerini tedavi etmek i\u00e7in onaylanm\u0131\u015f, b\u00fcy\u00fcyen bir imm\u00fcnoterapi ila\u00e7lar\u0131 s\u0131n\u0131f\u0131 olan kontrol noktas\u0131 inhibit\u00f6rlerinin de ya\u015fl\u0131 hastalar i\u00e7in g\u00fc\u00e7l\u00fc bir se\u00e7enek olabilece\u011fi sonucuna varmak mant\u0131kl\u0131d\u0131r. <\/span>Ancak bu her zaman b\u00f6yle olmayabilir, diyor Amerika Kanser Tedavi Merkezlerinde hassas t\u0131p t\u0131bbi direkt\u00f6r\u00fc Ankur Parikh. <\/span><\/span>\u00ae<\/span><\/span><\/sup> (CTCA) ve Philadelphia’daki Hastanemizde bir hematolog, onkolog ve t\u0131bbi onkolog.<\/span><\/span><\/p>\n

Ya\u015fa g\u00f6re yeni kanser vakalar\u0131n\u0131n y\u00fczdesi<\/span><\/span><\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
ya\u015flanmak<\/span><\/span><\/th>\nYeni Vaka <\/span>Y\u00fczdesi<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n
20’den<\/span><\/span><\/span><\/span><\/td>\nBirim%<\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
20 ya 34<\/span><\/span><\/span><\/span><\/td>\n%2.80<\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
35 44<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n%5<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
45 54<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n%13.30<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
55 64<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n%24.6<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
65 74<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n%27.20<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n
75 84<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n%18.30<\/span><\/span><\/span><\/span><\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

65 ya\u015f ve \u00fcst\u00fc ya\u015fl\u0131 hastalar ve ba\u011f\u0131\u015f\u0131kl\u0131k sistemi zay\u0131f olanlar, baz\u0131 gen\u00e7 hastalar\u0131n ya\u015fad\u0131\u011f\u0131 imm\u00fcnoterapiye g\u00fc\u00e7l\u00fc yan\u0131t vermeyebilir. <\/span>Ya\u015fl\u0131 hastalar\u0131n klinik ara\u015ft\u0131rmalara kat\u0131lma olas\u0131l\u0131klar\u0131 daha d\u00fc\u015f\u00fck oldu\u011fundan, bu tedavilere neden yan\u0131t verip veremedikleri konusunda daha az klinik veri mevcuttur. <\/span>Dr. Barrick, “\u0130mm\u00fcnoterapi kesinlikle bir\u00e7ok hastaya yard\u0131mc\u0131 oluyor ve belirli pop\u00fclasyonlarda \u00e7ok ilgin\u00e7 tepkiler g\u00f6r\u00fcyoruz” diyor. <\/span>“Bildi\u011fimiz \u015fu ki, hastalar\u0131n ba\u011f\u0131\u015f\u0131kl\u0131k sistemi zamanla de\u011fi\u015fiyor ve geli\u015fiyor. \u0130nsanlar ya\u015fland\u0131k\u00e7a ba\u011f\u0131\u015f\u0131kl\u0131k sistemi de de\u011fi\u015fiyor. Ve 65 ya\u015f\u0131ndaki bir ki\u015fi, 40 ya\u015f\u0131n alt\u0131ndaki biriyle ayn\u0131 \u015fekilde imm\u00fcnoterapiye yan\u0131t verir mi? Bu soru, hen\u00fcz cevaplanmad\u0131. Ve ne yaz\u0131k ki, bir\u00e7ok klinik \u00e7al\u0131\u015fmada b\u00fcy\u00fck bir ya\u015fl\u0131 n\u00fcfus yok. Bu y\u00fczden bu cevaplar\u0131 s\u0131k s\u0131k alam\u0131yoruz.”<\/span><\/span><\/p>\n

Kanser riskleri bir\u00e7ok nedenden dolay\u0131 ya\u015fla birlikte artar.<\/span><\/span><\/p>\n

    \n
  • H\u00fccre replikasyon hatalar\u0131 ya\u015fl\u0131larda daha s\u0131k meydana gelir ve bu da kansere yol a\u00e7abilecek bir DNA mutasyonu \u00fcretme \u015fans\u0131n\u0131 art\u0131r\u0131r. <\/span>Johns Hopkins \u00dcniversitesi T\u0131p Fak\u00fcltesi’ndeki ara\u015ft\u0131rmac\u0131lar taraf\u0131ndan 2017 y\u0131l\u0131nda yap\u0131lan bir ara\u015ft\u0131rma, h\u00fccreler s\u00fcrekli b\u00f6l\u00fcnd\u00fc\u011f\u00fcnde meydana gelen hatalar\u0131n t\u00fcm kanserlerin y\u00fczde 60’\u0131ndan fazlas\u0131ndan sorumlu olabilece\u011fi sonucuna vard\u0131.<\/span><\/span><\/li>\n
  • \u0130\u00e7ki, sigara ve k\u00f6t\u00fc beslenme gibi y\u0131llarca s\u00fcren al\u0131\u015fkanl\u0131klar zarar g\u00f6r\u00fcyor. <\/span>Yakla\u015f\u0131k 130.000 Amerikal\u0131 \u00fczerinde 2016 y\u0131l\u0131nda yap\u0131lan bir Harvard ara\u015ft\u0131rmas\u0131, sa\u011fl\u0131kl\u0131 bir ya\u015fam tarz\u0131 benimseyerek kanser riskinin y\u00fczde 40’a kadar azalt\u0131labilece\u011fini buldu.<\/span><\/span><\/li>\n
  • Asbest, pasif sigara duman\u0131, b\u00f6cek ila\u00e7lar\u0131 ve g\u00fcne\u015ften gelen ultraviyole \u0131\u015f\u0131nlar\u0131 gibi kanserojenlere ve \u00e7evresel risk fakt\u00f6rlerine maruz kalmak da riski art\u0131r\u0131r.<\/span><\/span><\/li>\n<\/ul>\n

    Biz daha gen\u00e7ken, h\u00fccrelerimiz, transkripsiyon veya maruz kalma hatalar\u0131ndan kaynaklanan DNA mutasyonlar\u0131n\u0131 s\u0131kl\u0131kla d\u00fczelten onar\u0131m mekanizmalar\u0131na sahiptir. <\/span>Ve d\u00fczeltmedikleri zaman, ba\u011f\u0131\u015f\u0131kl\u0131k sistemi muhtemelen hatal\u0131 h\u00fccrelere sald\u0131rmaya ve \u00f6ld\u00fcrmeye ba\u015flayacakt\u0131r. <\/span>Ancak ya\u015fland\u0131k\u00e7a, onar\u0131m mekanizmalar\u0131m\u0131z ba\u015far\u0131s\u0131z olmaya ba\u015flar ve ba\u011f\u0131\u015f\u0131kl\u0131k sistemlerimiz zay\u0131flar, bu da kusurlu h\u00fccrelerin kontrolden \u00e7\u0131kmas\u0131na ve bir t\u00fcm\u00f6r olu\u015fturmas\u0131na neden olabilir. <\/span>Bence ya\u015fl\u0131 hastalar i\u00e7in zorluk, ba\u011f\u0131\u015f\u0131kl\u0131k sistemlerinin neredeyse o kadar verimli olmayabilece\u011fi veya ba\u011f\u0131\u015f\u0131kl\u0131k ya\u015flanmas\u0131 denen bir \u015feyden muzdarip olmalar\u0131 olabilir. <\/span>\u00d6lmeyen ancak art\u0131k b\u00fcy\u00fcyemeyen veya b\u00f6l\u00fcnemeyen ya\u015flanm\u0131\u015f h\u00fccreler bazen kanser \u00f6ncesi \u00f6zelliklere sahiptir. <\/span>Ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccreleri de dahil olmak \u00fczere di\u011fer ya\u015flanan h\u00fccreler, zombi benzeri bir durumda var olabilir: canl\u0131, ancak d\u00fczg\u00fcn \u00e7al\u0131\u015fm\u0131yor. <\/span>Ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerinin kanser h\u00fccrelerini daha iyi tan\u0131mas\u0131na ve sald\u0131rmas\u0131na izin vermek i\u00e7in tasarlanm\u0131\u015f kontrol noktas\u0131 inhibit\u00f6rleri, ya\u015flanan ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerine sahip ya\u015fl\u0131 hastalarda kanserle sava\u015fmak i\u00e7in gerekli deste\u011fi sa\u011flayamayabilir. <\/span>Dr. Barrick, “J\u00fcri, imm\u00fcnoterapinin veya \u00f6zellikle ya\u015fl\u0131 hastalarda kontrol noktas\u0131 inhibit\u00f6rlerinin rol\u00fc konusunda h\u00e2l\u00e2 karars\u0131z” diyor.<\/span><\/span><\/span><\/span><\/p>\n

    \n

    \u0130mm\u00fcnoterapi t\u00fcrleri:<\/span><\/span><\/h3>\n
      \n
    • Kontrol noktas\u0131 inhibit\u00f6rleri, kanser h\u00fccrelerini daha iyi tan\u0131mak ve onlara sald\u0131rmak i\u00e7in ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerini aktive etmek \u00fczere tasarlanm\u0131\u015ft\u0131r.<\/span><\/span><\/li>\n
    • A\u015f\u0131lar, kansere neden olabilen vir\u00fcsleri engellemek veya ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerini bir t\u00fcm\u00f6re veya bir grup kanser h\u00fccresine \u00e7ekmek i\u00e7in tasarlanm\u0131\u015ft\u0131r.<\/span><\/span><\/li>\n
    • Sitokinler, ba\u011f\u0131\u015f\u0131kl\u0131k sistemini d\u00fczenlemeye ve y\u00f6nlendirmeye yard\u0131mc\u0131 olan protein molek\u00fclleridir.<\/span><\/span><\/li>\n
    • CAR T h\u00fccre tedavisi, belirli kanser h\u00fccrelerinin belirli \u00f6zelliklerini hedeflemek i\u00e7in yeniden tasarlanm\u0131\u015f T h\u00fccrelerini kullan\u0131r.<\/span><\/span><\/li>\n<\/ul>\n<\/div>\n

      Dr. Barrick, imm\u00fcnoterapinin ya\u015fl\u0131 hastalar \u00fczerindeki etkisine ili\u015fkin ara\u015ft\u0131rmalar\u0131n devam etti\u011fini, ancak ya\u015fl\u0131 hastalar\u0131n klinik deneylere g\u00f6n\u00fcll\u00fc olma olas\u0131l\u0131\u011f\u0131n\u0131n daha d\u00fc\u015f\u00fck olmas\u0131 nedeniyle klinik verilerin s\u0131n\u0131rl\u0131 olabilece\u011fini s\u00f6yl\u00fcyor. <\/span>Ek olarak, ya\u015fl\u0131 hastalarda kronik obstr\u00fcktif akci\u011fer hastal\u0131\u011f\u0131 (KOAH) veya kalp yetmezli\u011fi gibi onlar\u0131 klinik deneyler i\u00e7in uygun olmayan durumlar olabilir. <\/span>Dr. Barrick, “Yani bu \u00e7ok \u00f6nemli hasta grubunu ka\u00e7\u0131r\u0131yoruz” diyor. <\/span>Ancak doktorlar, her ya\u015ftan hasta i\u00e7in bir tedavi se\u00e7ene\u011fi olarak uygun oldu\u011funda imm\u00fcnoterapiye y\u00f6nelmeye devam edeceklerini s\u00f6yl\u00fcyor. <\/span>Dr. Barrick, “Bir kanser t\u00fcr\u00fcyle ba\u015far\u0131l\u0131 oldu\u011funuzda, ki\u015finin ya\u015f\u0131na g\u00f6re ayr\u0131mc\u0131l\u0131k yapmam” diyor. <\/span>“Onlara hala \u015f\u00fcphe uyand\u0131r\u0131yoruz ve uygun oldu\u011funda test ediyoruz.”<\/span><\/span><\/span><\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

      \u0130mm\u00fcnoterapi ya\u015fl\u0131 kanser hastalar\u0131na yard\u0131mc\u0131 olabilir, ancak… c Ya\u015fland\u0131k\u00e7a kanser riskleri \u00f6nemli \u00f6l\u00e7\u00fcde artar. Ulusal Kanser Enstit\u00fcs\u00fcne g\u00f6re, t\u00fcm yeni kanserlerin yar\u0131s\u0131ndan fazlas\u0131 65 ya\u015f ve \u00fcst\u00fc hastalarda te\u015fhis edilir ve yeni vakalar\u0131n y\u00fczde 25’inden fazlas\u0131 75 ya\u015f ve \u00fcst\u00fc hastalardad\u0131r. Bu nedenle, her ya\u015ftan hastada \u00e7e\u015fitli kanser t\u00fcrlerini tedavi etmek i\u00e7in onaylanm\u0131\u015f, b\u00fcy\u00fcyen bir …<\/p>\n","protected":false},"author":1,"featured_media":21699,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":["post-22987","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-tr"],"yoast_head":"\n\u0130mm\u00fcnoterapi ya\u015fl\u0131 kanser hastalar\u0131na yard\u0131mc\u0131 olabilir, ancak... - zdmaa<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u0130mm\u00fcnoterapi ya\u015fl\u0131 kanser hastalar\u0131na yard\u0131mc\u0131 olabilir, ancak... - zdmaa\" \/>\n<meta property=\"og:description\" content=\"\u0130mm\u00fcnoterapi ya\u015fl\u0131 kanser hastalar\u0131na yard\u0131mc\u0131 olabilir, ancak… c Ya\u015fland\u0131k\u00e7a kanser riskleri \u00f6nemli \u00f6l\u00e7\u00fcde artar. Ulusal Kanser Enstit\u00fcs\u00fcne g\u00f6re, t\u00fcm yeni kanserlerin yar\u0131s\u0131ndan fazlas\u0131 65 ya\u015f ve \u00fcst\u00fc hastalarda te\u015fhis edilir ve yeni vakalar\u0131n y\u00fczde 25’inden fazlas\u0131 75 ya\u015f ve \u00fcst\u00fc hastalardad\u0131r. Bu nedenle, her ya\u015ftan hastada \u00e7e\u015fitli kanser t\u00fcrlerini tedavi etmek i\u00e7in onaylanm\u0131\u015f, b\u00fcy\u00fcyen bir …\" \/>\n<meta property=\"og:url\" content=\"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/\" \/>\n<meta property=\"og:site_name\" content=\"zdmaa\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-11T14:00:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-12T07:45:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/man-g554c3a5b5_640.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"426\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tahmini okuma s\u00fcresi\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 dakika\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/\",\"url\":\"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/\",\"name\":\"\u0130mm\u00fcnoterapi ya\u015fl\u0131 kanser hastalar\u0131na yard\u0131mc\u0131 olabilir, ancak... - zdmaa\",\"isPartOf\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/man-g554c3a5b5_640.jpg\",\"datePublished\":\"2022-01-11T14:00:25+00:00\",\"dateModified\":\"2022-01-12T07:45:02+00:00\",\"author\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3\"},\"breadcrumb\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/#primaryimage\",\"url\":\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/man-g554c3a5b5_640.jpg\",\"contentUrl\":\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/man-g554c3a5b5_640.jpg\",\"width\":640,\"height\":426,\"caption\":\"Immunotherapy may help elderly cancer patients, but\u2026\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629\",\"item\":\"https:\/\/zdmaa.com\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u0130mm\u00fcnoterapi ya\u015fl\u0131 kanser hastalar\u0131na yard\u0131mc\u0131 olabilir, ancak…\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#website\",\"url\":\"https:\/\/zdmaa.com\/tr\/ro\/\",\"name\":\"zdmaa\",\"description\":\"zdmaa\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/zdmaa.com\/tr\/ro\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1775954700\",\"contentUrl\":\"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1775954700\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/zdmaa.com\"],\"url\":\"https:\/\/zdmaa.com\/tr\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u0130mm\u00fcnoterapi ya\u015fl\u0131 kanser hastalar\u0131na yard\u0131mc\u0131 olabilir, ancak... - zdmaa","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/","og_locale":"tr_TR","og_type":"article","og_title":"\u0130mm\u00fcnoterapi ya\u015fl\u0131 kanser hastalar\u0131na yard\u0131mc\u0131 olabilir, ancak... - zdmaa","og_description":"\u0130mm\u00fcnoterapi ya\u015fl\u0131 kanser hastalar\u0131na yard\u0131mc\u0131 olabilir, ancak… c Ya\u015fland\u0131k\u00e7a kanser riskleri \u00f6nemli \u00f6l\u00e7\u00fcde artar. Ulusal Kanser Enstit\u00fcs\u00fcne g\u00f6re, t\u00fcm yeni kanserlerin yar\u0131s\u0131ndan fazlas\u0131 65 ya\u015f ve \u00fcst\u00fc hastalarda te\u015fhis edilir ve yeni vakalar\u0131n y\u00fczde 25’inden fazlas\u0131 75 ya\u015f ve \u00fcst\u00fc hastalardad\u0131r. Bu nedenle, her ya\u015ftan hastada \u00e7e\u015fitli kanser t\u00fcrlerini tedavi etmek i\u00e7in onaylanm\u0131\u015f, b\u00fcy\u00fcyen bir …","og_url":"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/","og_site_name":"zdmaa","article_published_time":"2022-01-11T14:00:25+00:00","article_modified_time":"2022-01-12T07:45:02+00:00","og_image":[{"width":640,"height":426,"url":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/man-g554c3a5b5_640.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"admin","Tahmini okuma s\u00fcresi":"5 dakika"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/","url":"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/","name":"\u0130mm\u00fcnoterapi ya\u015fl\u0131 kanser hastalar\u0131na yard\u0131mc\u0131 olabilir, ancak... - zdmaa","isPartOf":{"@id":"https:\/\/zdmaa.com\/tr\/ro\/#website"},"primaryImageOfPage":{"@id":"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/#primaryimage"},"image":{"@id":"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/#primaryimage"},"thumbnailUrl":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/man-g554c3a5b5_640.jpg","datePublished":"2022-01-11T14:00:25+00:00","dateModified":"2022-01-12T07:45:02+00:00","author":{"@id":"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3"},"breadcrumb":{"@id":"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/#primaryimage","url":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/man-g554c3a5b5_640.jpg","contentUrl":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/man-g554c3a5b5_640.jpg","width":640,"height":426,"caption":"Immunotherapy may help elderly cancer patients, but\u2026"},{"@type":"BreadcrumbList","@id":"https:\/\/zdmaa.com\/tr\/immunotherapy-may-help-elderly-cancer-patients-but\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629","item":"https:\/\/zdmaa.com\/tr\/"},{"@type":"ListItem","position":2,"name":"\u0130mm\u00fcnoterapi ya\u015fl\u0131 kanser hastalar\u0131na yard\u0131mc\u0131 olabilir, ancak…"}]},{"@type":"WebSite","@id":"https:\/\/zdmaa.com\/tr\/ro\/#website","url":"https:\/\/zdmaa.com\/tr\/ro\/","name":"zdmaa","description":"zdmaa","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/zdmaa.com\/tr\/ro\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3","name":"admin","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/image\/","url":"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1775954700","contentUrl":"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1775954700","caption":"admin"},"sameAs":["https:\/\/zdmaa.com"],"url":"https:\/\/zdmaa.com\/tr\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts\/22987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/comments?post=22987"}],"version-history":[{"count":3,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts\/22987\/revisions"}],"predecessor-version":[{"id":23028,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts\/22987\/revisions\/23028"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/media\/21699"}],"wp:attachment":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/media?parent=22987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/categories?post=22987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/tags?post=22987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}